Palliative care alongside cancer treatment

    Whether to add specialist palliative care now, alongside cancer treatment, or to wait.

    Adults with advanced cancer who are still receiving or considering cancer treatment. The trials here studied adults with advanced cancer, one of them only people newly diagnosed with metastatic non-small-cell lung cancer.

    SourcedModeledNo projected outcomes are generated on this page.

    Pending clinical review. Each statement is paraphrased from the named source, but no clinician has reviewed this page yet. Use it to prepare questions, not to choose a treatment.

    What this decision concerns

    In standard cancer care, palliative measures generally begin when disease-modifying treatment has not worked, no treatment can be offered, or death is anticipated. Early palliative care starts much closer to the diagnosis of incurable cancer, alongside cancer treatment.

    SourcedCochrane systematic review · 2017

    The Cochrane review describes the evidence as low to very low certainty, drawn from a small number of trials that differed in who they enrolled and what care they gave. The choice is about timing and support, not about stopping cancer treatment.

    SourcedCochrane systematic review · 2017

    The options

    Add palliative care now, alongside cancer treatment

    Regular visits with a palliative care team while cancer treatment continues.

    • People given early palliative care had better quality of life at 12 weeks than those given standard cancer care alone (98.0 vs 91.5 on a 0 to 136 scale).

      Applies to: 151 adults newly diagnosed with metastatic non-small-cell lung cancer, at one US cancer center.

      SourcedMassachusetts General Hospital randomized trial · 2010

    • Fewer people in the early palliative care group had depressive symptoms (16% vs 38%).

      Applies to: The same trial, assessed at 12 weeks.

      SourcedMassachusetts General Hospital randomized trial · 2010

    • Median survival was longer with early palliative care (11.6 vs 8.9 months), although fewer people in that group received aggressive care at the end of life (33% vs 54%).

      Applies to: The same trial. Survival was not its primary outcome.

      SourcedMassachusetts General Hospital randomized trial · 2010

    • Across seven trials, early palliative care improved quality of life and lowered symptom intensity by small amounts, on low-certainty evidence.

      Applies to: 1614 adults with advanced cancer in seven randomized trials.

      SourcedCochrane systematic review · 2017

    • Pooled across trials, effects on survival and on depression were uncertain (very low certainty evidence).

      Applies to: Four trials (800 adults) for survival, five for depression.

      SourcedCochrane systematic review · 2017

    • One trial reported possible adverse events of early palliative care, such as more participants with severe pain or poor appetite scores. The other six trials did not report adverse events in their publications.

      Applies to: The seven trials in the Cochrane review.

      SourcedCochrane systematic review · 2017

    • In ENABLE III, early palliative care meant an in-person consultation, six weekly telehealth nurse coaching sessions, and monthly follow-up.

      Applies to: 207 adults with advanced cancer at a cancer center, a Veterans Affairs medical center and community clinics.

      SourcedENABLE III randomized trial · 2015

    Continue cancer care as it is, and consider palliative care later

    Usual cancer care for now. Palliative care can be added at any point.

    • Starting the same palliative care three months later did not produce statistically different quality of life, symptom impact or mood.

      Applies to: 207 adults with advanced cancer, early versus three months later.

      SourcedENABLE III randomized trial · 2015

    • Hospital days, intensive care days, emergency visits and home death were similar whether palliative care started early or three months later.

      Applies to: Participants in ENABLE III who died during the study.

      SourcedENABLE III randomized trial · 2015

    • One-year survival was 48% when palliative care began three months later, compared with 63% when it began early.

      Applies to: 207 adults with advanced cancer. The authors call the mechanism a research priority.

      SourcedENABLE III randomized trial · 2015

    • In the lung cancer trial, people given standard cancer care alone more often had depressive symptoms and more often received aggressive end-of-life care.

      Applies to: Adults newly diagnosed with metastatic non-small-cell lung cancer.

      SourcedMassachusetts General Hospital randomized trial · 2010

    Set against what matters to you

    Modeled

    Read from what you saved on this device.

    What sources report about what matters to you

    Nothing yet. Mark what matters to you, and anything the sources say about it shows up here.

    Pulls in two directions

    Nothing so far pulls against anything else.

    Still unknown

    • Nothing is marked as a priority yet, so nothing here is connected to what matters to you. The options and their sources are still readable below.

      Not in the sources here.

    • The Cochrane review rated the evidence low to very low certainty and noted differences between trials in participants, interventions and methods.

      Cochrane systematic review, 2017 statement

    • These trials studied people with cancer. Whether the findings apply to heart, lung, kidney or neurological illness is not answered here.

      Not in the sources here.

    • Whether a palliative care team is available where you are, and what it would cost you, is not carried in this record.

      Not in the sources here.

    Worth asking

    • Is there a palliative care team here, and can I see them while my cancer treatment continues?
    • What would palliative care add for me right now: symptoms, mood, planning, support for my family?
    • How often would I see them, and would it be in person, by phone or at home?
    • Will it cost me anything, and does my insurance or a public scheme cover it?
    • If I wait, when would we talk about it again?
    Start with what matters

    How this measures up

    Checked against IPDAS 5.0: 10 met, 0 partly met, 4 not met

    Sets source-backed statements about named options against what the person said matters. Does not meet the development and evaluation standard a patient decision aid requires. Three further stages would be needed to call it a patient decision aid: essential-criteria appraisal, an independent bias appraisal, and an evaluation of what it changes for the people who use it. None has been done. 4 criteria below are not fully met.

    Qualifying criteria

    • MetHealth conditionchecked automatically

      A source-backed description of the health condition or event is recorded separately from the option comparison.

    • MetExplicit decisionchecked automatically

      States the decision: "Whether to add specialist palliative care now, alongside cancer treatment, or to wait."

    • MetTarget audiencechecked automatically

      Names who this is for: "Adults with advanced cancer who are still receiving or considering cancer treatment. The trials here studied adults with advanced cancer, one of them only people newly diagnosed with metastatic non-small-cell lung cancer."

    • MetOptionschecked automatically

      2 options, including an explicit wait-or-decline option.

    • MetBenefitschecked automatically

      6 recorded statements read as supporting an option.

    • MetHarmschecked automatically

      5 recorded statements read as burdening an option.

    • Not metValues clarificationrecorded judgment

      Not assessed. An unassessed criterion is not a met one.

    Bias reduction

    • Not metBest available evidencechecked automatically

      3 primary sources cited, each paraphrased closely. Something that may supersede this source was found. A person has to decide. A person has to act on this before the row can pass.

    • Not metUser involvement in developmentrecorded judgment

      No patient, caregiver, or clinician took part in developing this journey. No usability or comprehension testing has been run on it.

    • MetNeutral presentation of optionschecked automatically

      Every option carries at least one statement in each direction, so no option is recorded as all upside or all downside.

    • MetComplete citationschecked automatically

      3 sources, each with a full citation, a resolving identifier, a publication date, and the date and route it was read.

    • MetPublication or version datechecked automatically

      Last reviewed 2026-11-14.

    • Not metUpdate policyrecorded judgment

      Each journey records when it was last reviewed. A recheck cadence and triggers are proposed, and source recheck due dates are computed from them, but no owner has adopted the policy. This stays unmet until one does.

    • MetFunding disclosedrecorded judgment

      Funding and editorial independence are stated at /independence.

    Screening decisions

    • Not applicableWhat the test measureschecked automatically

      This journey is not a screening decision.

    • Not applicableConsequences of a positive resultchecked automatically

      This journey is not a screening decision.

    • Not applicableNext steps after either resultchecked automatically

      This journey is not a screening decision.

    • Not applicableOverdiagnosis and false positiveschecked automatically

      This journey is not a screening decision.

    This checks the seven IPDAS 5.0 qualifying criteria, seven bias-reduction criteria, and four screening-specific criteria against what each journey holds. IPDAS 5.0 contains more than these. A criterion absent here has not been assessed and is not passed. Standard: IPDAS 5.0, published 2026-06-12. Assessment is by Values in Care, not by IPDAS or any outside reviewer.

    Sources

    Sourced
    • Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733-742.

      https://doi.org/10.1056/NEJMoa1000678

      Read 2026-11-14 from the PubMed record (structured abstract of the version of record).

      Currentness check · 2026-11-14

      A randomized trial is not superseded by later trials. Later trials and reviews add to it rather than replace it.

      Method: PubMed search via the PubMed MCP connector for later randomized trials of early integrated palliative care in advanced cancer.

      Not covered: Corrections or later reanalyses of this trial were not searched for separately.

      Adjacent evidence, not incorporated into this journey: Vanbutsele et al., Lancet Oncol 2018;19(3):394-404 (PMID 29402701), a Belgian randomized trial of 186 adults with advanced solid tumors, reported better quality of life at 12 weeks with early systematic palliative care, in a setting where psychosocial oncology care was already standard. A clinical reviewer should decide whether it belongs in this journey.

    • Haun MW, Estel S, Rücker G, et al. Early palliative care for adults with advanced cancer. Cochrane Database Syst Rev. 2017;6(6):CD011129.

      https://doi.org/10.1002/14651858.CD011129.pub2

      Read 2026-11-14 from the PubMed record (structured abstract of the version of record).

      Currentness check · 2026-11-14

      No updated Cochrane review is indexed. Two later non-Cochrane meta-analyses pool more trials: Haroen et al., BMC Palliat Care 2025;24:120 (24 studies, PMID 40296046), and Huo et al., Eur J Cancer Care 2022;31:e13620 (16 studies, PMID 35612356). Either may supersede the 2017 review as the best current synthesis; a person has to decide.

      Method: PubMed searches via the PubMed MCP connector: Cochrane Database Syst Rev for "early palliative care", and systematic reviews or meta-analyses of early palliative care in cancer published after June 2017.

      Not covered: Cochrane's own list of protocols and updates in progress was not checked, and neither later review's methods were appraised.

    • Bakitas MA, Tosteson TD, Li Z, et al. Early versus delayed initiation of concurrent palliative oncology care: patient outcomes in the ENABLE III randomized controlled trial. J Clin Oncol. 2015;33(13):1438-1445.

      https://doi.org/10.1200/JCO.2014.58.6362

      Read 2026-11-14 from the PubMed record (structured abstract of the version of record).

      Currentness check · 2026-11-14

      No later trial of the same early-versus-delayed comparison was identified in the results reviewed.

      Method: PubMed search via the PubMed MCP connector for later randomized trials comparing early with delayed palliative care.

      Not covered: Only the first results of each search were reviewed; trial registries were not searched.

    Each clinical statement above paraphrases one of these sources closely. Filing it under a priority, or reading it against priorities you saved, is a Values in Care editorial operation rather than a source finding.

    Open Source Watch